HIV & women — your body, your care, your life.

For the first decade of the epidemic, the AIDS case definition did not include the conditions women actually got, and women were excluded from most early trials on the theory that hormones complicated the data. The result is a knowledge base built largely on men's bodies and then applied to everyone — which is why so much of what women living with HIV need to know had to be won, cohort by cohort, guideline by guideline, by advocates who insisted the questions get asked.

A lot has been won: a forty-year observational cohort of women living with HIV in the United States, prevention products tested first in women rather than last, and perinatal guidance that treats an undetectable viral load as the fact it is. A woman diagnosed today, started on treatment promptly, and kept in care can expect a full life — pregnancies if she wants them, none if she doesn't, a career, sex, menopause, grandchildren, old age.

There are also real gaps, and this page names them: weight gain on modern regimens that hits women hardest, hormone therapy that goes unprescribed, screening intervals many providers don't know, violence rates no clinic questionnaire fully captures, and a burden concentrated on Black and Latina women by structures that have nothing to do with anyone's choices.

The numbers — who is actually affected, and where

Start with the surveillance data, because the picture in most people's heads is a decade or two out of date. In 2024, there were 38,793 new HIV diagnoses among people aged 13 and older in the United States and six dependent areas. Women accounted for 7,752 of them — about 20% — and men for 30,975.1 By the end of 2024, an estimated 1,158,701 people were living with diagnosed HIV in the U.S.1

Inside that 20%, the distribution is extremely uneven. Black women accounted for 52% of new diagnoses among women while representing roughly 13% of the U.S. female population. The rate among Black women was 21.6 per 100,000, compared with 6.4 among Hispanic/Latina women and 1.8 among White women — a roughly twelve-fold difference between Black and White women.1 That is not a statement about behavior. Rates that differ twelve-fold across racial groups within one country describe who has stable housing, insurance, transportation, a nearby clinic, and a provider who offers PrEP without being asked.

Geography: the epidemic among women is a Southern epidemic

The South accounted for 19,785 of all 2024 diagnoses — 51% — with a regional rate of 17.7 per 100,000, higher than any other region.1 For women this geography matters enormously: the South is also where Medicaid expansion is most incomplete, public transit thinnest, and HIV criminalization statutes still on the books. A woman in Tampa or Montgomery is navigating the same virus as a woman in Boston with a fraction of the infrastructure.

How transmission happens for women

Heterosexual contact is the dominant route. Florida's surveillance makes it concrete: of 996 adult women diagnosed in Florida in 2023, 909 were attributed to heterosexual contact and 84 to injection drug use.2 Nationally, injection-drug-attributed diagnoses among women skew differently by race — White women accounted for 46% of diagnoses among women attributed to injection drug use.1 Two different epidemics among women, requiring two different responses, often served by the same underfunded clinic.

Age

Nationally, ages 25–34 accounted for 14,183 diagnoses in 2024, and ages 25–44 for about 60% of all diagnoses.1 But among women living with HIV the age curve shifts sharply upward. In Florida, of 32,638 women living with diagnosed HIV at the end of 2023, 19,422 were 50 or older — nearly 60%.2 The center of gravity in women's HIV care has moved to midlife and beyond, which is why menopause, bone health, and cardiovascular risk belong in this article and not in a footnote.

The first year — what a new diagnosis actually looks like

If you were diagnosed recently, the most useful thing to know is that the emergency you are feeling and the medical urgency are two different things. The medical part is now remarkably straightforward; the emotional part takes longer, and that is not a sign anything is wrong with you.

Our companion page on being newly diagnosed walks through the first ninety days in detail. Here is what is specific to women.

Diagnosis often comes later, through a side door

Many women are diagnosed during pregnancy screening, during a workup for something else, or after a partner tests positive — not because they asked for an HIV test. Symptoms that might have prompted testing get attributed to something else first: recurrent vaginal candidiasis, persistent pelvic inflammatory disease, abnormal cervical cytology that keeps recurring, unexplained fatigue, weight loss. Our page on HIV symptoms in women covers that pattern. Later diagnosis means less time to prevent immune damage, so if a provider has ever called your recurrent gynecologic problem "just one of those things," an HIV test is a reasonable ask.

Rapid start is the standard

Treatment should begin as soon as possible after diagnosis — often the same day — rather than waiting for a full battery of results. In pregnancy this is explicit federal guidance: antiretroviral therapy should be started immediately and should not be withheld or delayed out of concern about preterm birth or hypertensive disorders of pregnancy.8 Outside pregnancy the logic is the same: every week of untreated viremia is immune activation you don't get back.

What forty years of watching women taught us

Almost everything specific we know about the long arc of HIV in women's bodies comes from one research program. The Women's Interagency HIV Study (WIHS) enrolled 4,982 women beginning in 1993–1994; the Multicenter AIDS Cohort Study (MACS) had begun in 1984 with 7,300 gay and bisexual men. In April 2019 the two merged into the MACS/WIHS Combined Cohort Study (MWCCS) under the National Heart, Lung, and Blood Institute — 13 sites, 5,844 enrolled participants as of May 2025, more than 3,400 publications, and over 12,000 people ever enrolled across forty years, making it the largest and longest-running cohort of women living with HIV in the United States.3

Two things matter about that cohort. Its participants are disproportionately Black and Hispanic women — more than three-quarters of those recruited since the 2019 merger — so the findings describe the women most affected. And its center of gravity is now older adults: 69% of participants living with HIV are over 50 and 21% are over 65.3 When a claim in this article concerns menopause, cardiovascular risk, depression, or violence, MWCCS is often where it came from.

Modern treatment — and the weight-gain story nobody warned women about

First-line antiretroviral therapy for most adults is a single tablet built around an integrase strand transfer inhibitor: bictegravir with emtricitabine and tenofovir alafenamide, or dolutegravir plus two nucleoside analogues. These regimens are potent, well tolerated, forgiving of an occasional late dose, and effective across essentially all baseline viral loads. Federal perinatal guidance now lists bictegravir/emtricitabine/tenofovir alafenamide as a Preferred regimen both in pregnancy and for people trying to conceive who have no prior antiretroviral or long-acting cabotegravir exposure — a meaningful vote of confidence in a drug class that women were once told to avoid if they might get pregnant.8

The weight signal is real, and it is worst in women

One side effect was undersold badly in the early rollout, and women bore most of it. The ADVANCE trial, conducted in South Africa in a predominantly female population, followed participants for 192 weeks on three regimens. Mean weight gain was 8.9 kg on tenofovir alafenamide/emtricitabine plus dolutegravir, 5.9 kg on tenofovir disoproxil fumarate/emtricitabine plus dolutegravir, and 3.2 kg on tenofovir disoproxil fumarate/emtricitabine/efavirenz. Gain was greatest among women, among people taking tenofovir alafenamide, and among those with lower baseline CD4 counts, and the trajectory slowed after week 96 rather than continuing indefinitely.6

The sex difference is starkest in who crossed into clinical obesity. Among women in ADVANCE, 43% on tenofovir alafenamide/emtricitabine/dolutegravir met criteria for obesity by week 192, versus 27% on tenofovir disoproxil fumarate/emtricitabine/dolutegravir and 20% on the efavirenz arm.6 A U.S. analysis in women in the WIHS cohort who switched to an integrase inhibitor found 22% experienced clinically significant weight gain of at least 7% over eighteen months, compared with 14% of women who did not switch.7

When a switch makes sense

Regimen changes are reasonable to discuss for persistent side effects, significant weight gain with worsening metabolic markers, interactions with contraception or other medications, simplification, or pregnancy planning. What a switch should not be is a unilateral decision made in frustration. Bring the specific problem and your numbers, and ask what the alternatives cost in resistance risk, pill burden, and food requirements.

Reproductive choice — every option is a real option

Women living with HIV are still routinely told, implicitly or explicitly, what their reproductive future should be — by a provider who assumes a diagnosis ends the conversation about children, or by one who assumes a woman of childbearing age must want a pregnancy. Both are the same error.

The correct framing is that all of the following are complete, legitimate, medically supportable choices: having biological children, having more after a diagnosis, having none, having them later, adopting, fostering, using a surrogate, or deciding the question is nobody else's business. HIV changes the logistics of some of these paths. It does not remove any of them from the menu.

U=U and conception in a mixed-status couple

Undetectable equals untransmittable is not restricted to men who have sex with men, and not restricted to sex that isn't trying to make a baby. Federal perinatal guidance frames conception around exactly this: sustained viral suppression is the foundation, and the recommendation to be on effective treatment applies to people trying to conceive as much as to people already pregnant.8

In practice, for a mixed-status couple, that means the conversation runs through a short list:

• If the partner living with HIV is the woman: sustained viral suppression before conception protects her health and drives perinatal risk to well under 1%.8 Her HIV-negative partner cannot acquire HIV from her while she is durably suppressed.
• If the partner living with HIV is the man: sustained suppression means condomless timed intercourse carries no risk of sexual transmission to her. Where suppression is not established or not durable, PrEP for her, sperm washing with intrauterine insemination, or in vitro fertilization are the standard alternatives to discuss with a fertility service.
• If both partners are living with HIV: the conversation is about viral suppression, resistance history, and regimen suitability in pregnancy — not about whether to proceed.
• Preconception care is real care. Folic acid, vaccinations, blood pressure, thyroid, diabetes screening, current cervical screening, and a regimen review all belong before the positive pregnancy test.

Fertility deserves an honest mention

Reproductive aging appears to run somewhat faster in women living with HIV. In the Women's Interagency HIV Study, age-adjusted anti-Müllerian hormone — the marker of remaining ovarian reserve — was 16% lower with well-controlled HIV than in women without HIV, and 26% lower with detectable viremia, with levels tracking CD4 count regardless of serostatus.18 That is not a prediction about any individual. It is a reason not to be told "you have plenty of time" without a conversation, and to raise fertility timing early if biological children are something you want.

Contraception — what interacts, what doesn't, and who decides

Contraception in the context of HIV has a bad history. Women living with HIV have been pushed toward long-acting methods they didn't choose, discouraged from methods they wanted, and in some settings sterilized without meaningful consent. The Positive Women's Network–USA bodily autonomy framework names the correct standard directly: access to pregnancy prevention tools that a woman can use without a partner's knowledge if she needs to, trauma-informed care, and an affirmed right to refuse care.20

So the medical content below is not a recommendation about what you should use. It is the interaction information you are entitled to have while you decide.

The one interaction that has actually changed pregnancy rates

The clearest clinically significant interaction is between efavirenz and progestin contraceptive implants. Efavirenz-based therapy reduced levonorgestrel levels by 61% and etonogestrel by 49% in one pharmacokinetic study, and etonogestrel exposure was 82% lower at 24 weeks in another. A Kenyan cohort found adjusted pregnancy incidence of 3.3 per 100 woman-years among implant users on efavirenz-based therapy versus 1.1 on nevirapine-based therapy.11

Two pieces of context, from the same review. First, even with that reduction, pregnancy rates among implant users on efavirenz remained lower than pregnancy rates with most non-long-acting methods — an implant on efavirenz is still a good contraceptive, just not as spectacularly good as an implant usually is.11 Second, efavirenz is no longer a first-line regimen in the United States, so for most women reading this the interaction is historical rather than current.

What the rest of the interaction table looks like

• Nucleoside analogues (tenofovir, emtricitabine, abacavir, lamivudine): no reported effect on combined hormonal contraception, implants, or DMPA.11
• Integrase inhibitors (dolutegravir, bictegravir, raltegravir): reported effects on combined hormonal contraception range from increased progestin exposure to no change, with no reported increase in contraceptive failure.11 This is the reassuring row, and most women on modern therapy are in it.
• Protease inhibitors (especially ritonavir-boosted): increased progestin and decreased ethinyl estradiol with combined hormonal contraception; increased progestin exposure with progestin-only pills, implants, and DMPA. Clinical consequences remain unclear.11
• The levonorgestrel IUD is Category 1/2 with antiretroviral therapy under CDC medical eligibility criteria — no change in serum levonorgestrel, no difference in viral load, no difference in pregnancy rates. A fully viable long-acting option.11
• The DMPA injection is also Category 1/2 for all antiretroviral regimens; most evidence shows no clinically significant implications from concurrent use, and initiating DMPA was not associated with increased HIV genital shedding over six months.11
• Emergency contraception: in HIV-negative volunteers taking efavirenz, levonorgestrel emergency contraception exposure fell 56% and peak concentration 41%.11 If you take an efavirenz-containing regimen and need emergency contraception, say so — a copper IUD or ulipristal may be discussed.
• Contraception does not appear to compromise your HIV treatment. Studies found no significant association between hormonal contraception and plasma viral suppression or genital HIV shedding.11

Pregnancy, birth, and infant feeding — where the guidance changed

Our dedicated page on HIV pregnancy planning covers this ground step by step. What follows is the current federal framework and the two places it has recently shifted.

Antiretroviral therapy in pregnancy

The Department of Health and Human Services Perinatal Guidelines — updated June 2026 — are the operative document. Bictegravir/emtricitabine/tenofovir alafenamide is Preferred in pregnancy and for people trying to conceive without prior antiretroviral or long-acting cabotegravir exposure. Dolutegravir/lamivudine is an Alternative where viral load is at or below 500,000 copies/mL, there is no hepatitis B coinfection, lamivudine susceptibility is confirmed, and there is no prior long-acting cabotegravir exposure. And antiretroviral therapy should not be withheld or delayed to try to prevent preterm birth or hypertensive disorders of pregnancy.8

The dolutegravir scare, and how it resolved

In 2018 an unscheduled interim analysis from the Tsepamo birth-outcomes study in Botswana reported four neural tube defects among 426 infants born to women taking dolutegravir at conception — roughly 0.9% against a background of about 0.1%. Regulators issued precautionary advice worldwide, and many women were abruptly told to avoid a drug that was otherwise excellent for them.

The signal did not hold up. Birth-defect surveillance in Eswatini across 2020–2021 found neural tube defect prevalence of 0.08% among 4,902 women on dolutegravir at conception — identical to the 0.08% among 17,285 women without HIV, and lower than the 0.15% on efavirenz. Pooling Eswatini and Botswana data across more than 14,000 births with dolutegravir at conception gave a weighted prevalence of 0.10%, and the authors concluded the data do not support an association.10 The episode shows pharmacovigilance working — and the cost of raising a signal in a population with almost no dedicated pregnancy research: years of women counseled out of a good drug on the basis of four cases, because the trials that would have answered the question earlier had never included them.

Delivery

Mode of delivery follows viral load, not HIV status. Cesarean delivery at 38 weeks is recommended when viral load is above 1,000 copies/mL or unknown near the time of birth; extending beyond 38 weeks may be considered with expert consultation. Fetal scalp electrodes should not be used. The National Perinatal HIV/AIDS Clinical Consultation Center is available to clinicians at 1-888-448-8765 — a number worth knowing if your delivery team seems uncertain.8

Infant feeding — the 2023 shift that changed the conversation

For decades, U.S. guidance was simply that people with HIV should not breastfeed. That changed in January 2023, when updated federal clinical guidelines began supporting shared decision-making on infant feeding: the risk of postnatal transmission is zero with properly prepared formula or pasteurized donor milk, and less than 1% — though not zero — with sustained undetectable viral load through pregnancy and postpartum. Clinicians are directed to support either choice.9

The guidance also includes a sentence many women living with HIV waited years to see in a federal document: it is inappropriate to engage Child Protective Services or similar services in response to a parent's infant feeding choices.9

The current perinatal guidelines operationalize this. If antiretroviral therapy has been consistent and viral load under 50 copies/mL for at least three months before delivery, counseling should cover formula, banked donor milk, or breastfeeding. Breastfeeding should stop if viral load reaches 200 copies/mL or viremia is presumed, and infant prophylaxis continues until four weeks after the last breast-milk exposure. Mastitis is managed by feeding from the unaffected breast, and hepatitis B or C coinfection is not a contraindication.8

Cervical and anal health — the screening most women aren't told about

This is where routine gynecologic care and HIV care are supposed to meet, and most often fail to. Human papillomavirus behaves differently in the setting of HIV, the screening intervals are different, and many women living with HIV have never been told either fact.

What HPV does differently

Federal opportunistic infection guidelines are direct: women with HIV have high incidence and persistence of HPV infection, high rates of cervical intraepithelial neoplasia including CIN3, and elevated rates of invasive cervical cancer — with cervical cancer rates roughly three to four times those in the general population. Effective antiretroviral therapy decreases incident HPV detection, persistence, and progression, and people who have been vaccinated still need routine screening.12 The World Health Organization, reviewing global evidence in December 2023, put the increased cervical cancer risk for women living with HIV at six-fold.13

The mechanism is clearance. Without HIV, roughly 90% of HPV infections clear on their own within about two years; with HIV, clearance is slower and less complete, so more infections persist long enough to cause the cellular changes that become cancer. That is why the answer is more frequent screening rather than a different test.

Screening cadence

WHO now recommends primary HPV DNA testing every three to five years starting at age 25 for women living with HIV, compared with every five to ten years for the general population.13 U.S. practice for women with HIV is generally cervical cytology at HIV diagnosis and annually while results are normal, extending to every three years after three consecutive normal results, with HPV co-testing added from age 30.12 The specifics of your interval belong to your clinician; the point is that "once every five years, like everyone else" is not the standard for you.

HPV vaccination — including as an adult

Routine HPV vaccination is recommended at ages 11–12, can begin at 9, and catch-up is recommended through age 26. For adults aged 27 through 45, the Advisory Committee on Immunization Practices recommends shared clinical decision-making rather than routine vaccination, with a three-dose series at 0, 2, and 6 months — three doses being the schedule for immunocompromised people who start the series.14 If you are in your thirties or early forties and were never vaccinated, this is a conversation you are entitled to initiate.

Menopause — earlier for some, undertreated for most

Menopause is where women's HIV care most visibly runs out of road. Our page on HIV and menopause goes deeper; here is the evidence and the advocacy script.

Does HIV bring menopause earlier? Honestly: probably somewhat, and the literature disagrees

The most useful single study analyzed 3,059 women with or at risk for HIV in the Women's Interagency HIV Study, 2008–2020. Overall, 1% had premature menopause before age 41, 3% had early menopause at 41–45, and 21% reached menopause at 46–50. Among the 2,164 women living with HIV specifically, 445 — 21% — reached menopause before 51, including 1% premature, 4% early, and 15% at ages 46–50.16

Earlier work pointed the same direction with a mechanism attached: a large cohort analysis found median age at menopause of 46 among women with HIV versus 47 among women without, and 42.5 years among women with CD4 counts below 200 — implicating immunosuppression rather than HIV itself.16 The wider literature is mixed: reviews put age at menopause for women living with HIV in the 46–50 range, most but not all studies show an earlier transition, and some analyses within WIHS found no significant difference. The defensible statement is that earlier menopause and primary ovarian insufficiency are more common among women living with HIV, particularly with a history of low CD4 counts, and that your own trajectory is not predictable from population data.16

The finding that should make everyone angry

The same WIHS analysis measured whether women with early or premature menopause actually received hormone therapy. Among those with menopause before 41, any oral hormone use was recorded for 51% of women — but at only 18% of visits. For menopause at 41–45: 24% of women, 11% of visits. For 46–50: 7% of women and 4% of visits. The authors concluded there is substantial unmet need for guideline-based hormone treatment.16

That gap matters beyond hot flashes. Premature and early menopause carry documented consequences for bone density and cardiovascular risk, and a broader review of cardiovascular disease in women living with HIV notes that in high-resource settings, hormonal therapy for early menopause is prescribed at inappropriately low rates.18 Two independent literatures, same conclusion: the treatment exists and women living with HIV are not getting it.

How to advocate if your provider hesitates

• Name it as a diagnosis, not a complaint. "I think I'm in perimenopause and I'd like it evaluated" lands differently from "I've been sleeping badly."
• Ask which specific contraindication applies to you. Hormone therapy has real contraindications. "You have HIV" is not one of them, and neither is a modern integrase-inhibitor regimen.
• Ask who manages this. Many HIV clinicians do not consider menopause their department, and many gynecologists defer to the HIV clinician. Insist that someone own it, and ask for a referral in writing.
• Separate the symptoms. Vasomotor and genitourinary symptoms, mood, sleep, bone density, and cardiovascular risk have different treatments; a blanket "no" to hormones is not a plan for any of them.
• Ask for a bone density baseline if you are postmenopausal or have had early menopause, and for lipids and blood pressure to be tracked, since both risk curves change at the transition.18

Safety — intimate partner violence, disclosure, and criminalization

This is the hardest part of the article to read and one of the most important. Violence is not a side topic in women's HIV care; it determines whether a woman can get to a clinic, take a daily pill, keep a bottle in her house, or tell anyone her status.

The prevalence

A meta-analysis of studies of women living with HIV in the United States estimated the rate of intimate partner violence at 55.3% (95% CI 36.1–73.8%) — more than twice the national rate for women — and the rate of recent post-traumatic stress disorder at 30.0% (95% CI 18.8–42.7%), over five times the rate in a national sample of women.17 Long-term cohort data are consistent: in a twenty-year analysis of gender-based violence in WIHS, 61% of participants reported a history of gender-based violence at study entry, and over follow-up 10% reported sexual violence and 21% physical violence.17

Disclosure itself carries risk. Roughly 24% of women living with HIV experience abuse after disclosing their status, and about 20% report violence from a partner since diagnosis.17 This is why "just tell your partner" is not neutral advice, and why any clinic that hands out disclosure scripts without asking about safety is doing half a job.

How criminalization compounds it

Many states still criminalize HIV non-disclosure, exposure, or transmission. In practice these laws hand an abusive partner a weapon: the threat to report, accurately or not, that disclosure did not happen. Positive Women's Network–USA lists ending HIV criminalization and ending violence against women living with HIV among its six core policy priorities precisely because they are the same fight.20 Its bodily autonomy framework frames the right to enjoy sex free from fear of HIV criminalization as a baseline condition, not an aspiration.20

Aging with HIV — the cardiovascular story is a women's story

Most women living with HIV in the United States are now in midlife or older — nearly 60% of those with diagnosed HIV in Florida are 50 or above2 — and 69% of MWCCS participants living with HIV are over 50, with 21% over 65.3 So the questions that matter most are increasingly the ordinary questions of aging, arriving early and harder.

The MWCCS cohort profile shows what that looks like. At a 2018–2019 study visit, among 2,115 women and 1,901 men with a median age of 56, the common conditions were dyslipidemia in 64%, hypertension in 56%, obesity in 42%, impaired activities of daily living in 31%, depressive symptoms in 28%, and diabetes in 22%.3 That is a chronic-disease profile, not an infectious-disease profile.

Cardiovascular disease

The sex pattern here is the opposite of what most people expect. In sex-stratified analyses, HIV-related cardiovascular risk is 1.5 to 2-fold higher for women than for men living with HIV, and women living with HIV carry roughly double the cardiovascular hazard of women without HIV.18 The specific numbers are striking:

• Myocardial infarction: relative risk 2.98 for women living with HIV versus women in the general population, against 1.40 for men living with HIV versus men without HIV — same cohort, adjusted for traditional risk factors.18
• Stroke: adjusted incident rate ratio 1.76 for women living with HIV versus women without HIV; not significant among men in the same analysis.18
• Heart failure: relative risk 3.67 for women living with HIV versus women without HIV in a meta-analysis of more than 8 million participants; in a Kaiser cohort, adjusted hazard ratio 2.48 for women versus 1.57 for men.18
• "Excess heart age": among 3,086 participants in the HIV Outpatient Study, women living with HIV aged 50–59 had an excess heart age of 16.1 years — higher than men living with HIV in every age group, against 5.4 years in the general U.S. female population.18
• Treatment gap: optimal therapy for heart failure with reduced ejection fraction was received by 40% of women living with HIV versus 83% of women without HIV.18 Partly the disease, partly the prescribing.

Mechanistically the drivers overlap: traditional risk factors, metabolic dysregulation including the weight and lipid effects of some regimens, early reproductive aging, and chronic immune activation. Women living with HIV with undetectable anti-Müllerian hormone had a higher burden of coronary plaque than those with normal levels, even after adjusting for age and cardiovascular risk factors.18 Women living with HIV were also less likely than men living with HIV to have completed high school, to hold private insurance, or to live above the federal poverty line.18 Biology and structure are not separable here.

Bone and brain

Bone health deserves attention at the menopause transition, when estrogen loss and any accumulated antiretroviral or inflammatory effect on bone converge — one more reason the hormone-therapy prescribing gap is not cosmetic.16 Cognition, physical function, and frailty are active areas of MWCCS research, supported by a biorepository of roughly 5.4 million specimens, with 1,771 incident cancers documented in the cohort between 1984 and 2024.3 If your memory or your walking speed has changed, that is a legitimate thing to raise.

Mental health — trauma-informed care is the standard, not a nicety

Depressive symptoms were present in 28% of MWCCS participants at a recent study visit.3 Recent PTSD affects roughly 30% of women living with HIV in the United States — five times the general-population rate for women — and lifetime intimate partner violence affects a majority.17 Those three facts together explain why mental health is not an add-on service in women's HIV care.

Trauma-informed care means something specific and operational, not a general attitude of kindness. It means asking about safety before asking about disclosure, not treating a missed appointment as a character assessment, and recognizing that a pelvic exam can be a trauma trigger — saying so out loud changes how the exam goes. It means the word "adherence" instead of "compliance," because one describes a shared plan and the other describes obedience. HRSA's Ryan White Part D program has made trauma-informed care one of its formal Communities of Practice focus areas — evidence that the system knows the gap exists.19

What actually helps

• Ask for behavioral health inside your HIV clinic. Integrated care beats a referral across town, and Ryan White Part D programs commonly fund behavioral health, case management, nutrition, and transportation alongside medical care.19
• Peer support is not a consolation prize. Organizations built by and for women living with HIV — SisterLove, Positive Women's Network–USA, Iris House — exist because a general support group does not cover this specific experience.21
• Screen for the treatable things too. Fatigue, low mood, and brain fog can also be thyroid disease, anemia, sleep apnea, vitamin deficiency, or perimenopause; a mental health diagnosis should not close the workup.
• If your provider's response to your distress is to question your adherence, that is a poor response. The direction of causation usually runs the other way.

Racial disparities — naming the actual mechanisms

Black women accounted for 52% of new HIV diagnoses among women in 2024 while representing about 13% of the U.S. female population, at a rate of 21.6 per 100,000 against 1.8 among White women.1 No individual-level explanation accounts for a twelve-fold gap. The mechanisms are structural and specific:

• Insurance and Medicaid geography. The epidemic among women is concentrated in the South, which had 51% of all 2024 diagnoses at the highest regional rate,1 and which overlaps heavily with the states where Medicaid expansion never happened. Coverage determines whether a diagnosis is followed by care.
• Prevention access. PrEP works and reaches Black women least. The breakthroughs described below — long-acting injectable cabotegravir and twice-yearly lenacapavir, both tested first in African women — only matter if they are stocked, covered, and offered without a woman having to ask.
• Sexual network effects. Mass incarceration and residential segregation concentrate HIV prevalence within networks, so identical individual behavior carries different exposure probability depending on where you live. The risk sits in the structure, not the person — which is why labelling any group of women as inherently risky is both stigmatizing and analytically wrong.
• Housing and economic precarity. Women living with HIV are less likely than men living with HIV to hold private insurance or live above the federal poverty line.18 Housing instability predicts falling out of care more reliably than almost any clinical variable.
• Medical mistrust with a documented basis. Coercive sterilization, unconsented research, and dismissal of Black women's reported symptoms are history and current experience. Mistrust is an accurate risk assessment, not a knowledge deficit to be corrected with a pamphlet.
• Provider bias in what gets offered. The heart failure treatment gap — 40% of women living with HIV receiving optimal therapy versus 83% of women without HIV18 — and the hormone therapy prescribing gap16 are both about what clinicians offer, not what women accept.
• Criminalization. HIV-specific statutes fall hardest on Black women, and they suppress testing, disclosure, and trust in the health system.2022

Latina women sit in a related but distinct position — a rate of 6.4 per 100,000, more than three times that of White women1 — with immigration status, language access, and fear of public-charge consequences layered on top. Our pages on HIV in Black communities and HIV in Latino communities take both up in detail.

Prevention research that finally centered women

Two trials are worth knowing by name, because they reversed the usual order in which women get studied.

Florida — the numbers and the access map

Florida is where the national pattern is most visible, and its local data are detailed enough to be useful.

In 2023, Florida recorded 4,725 HIV diagnoses across all ages, a rate of 20.8 per 100,000, and 1,981 AIDS diagnoses. Among adults, 996 women were diagnosed — 21% of adult diagnoses — of whom 629 were Black, 189 Hispanic/Latina, and 169 White. The Black female HIV diagnosis rate was 41.6 per 100,000, against 7.2 among Hispanic/Latina women and 3.1 among White women. Of those 996 diagnoses, 909 were attributed to heterosexual contact and 84 to injection drug use.2

At the end of 2023, 32,638 women were living with diagnosed HIV in Florida — 25% of adults living with HIV in the state — including 21,252 Black women, 5,809 Hispanic/Latina women, and 4,908 White women. The age distribution is the headline: 19,422 of those women were 50 or older, 7,138 were 40–49, 4,504 were 30–39, 1,465 were 20–29, and 109 were 13–19.2

Florida's seven Ending the HIV Epidemic counties carried the highest 2023 counts and rates: Miami-Dade (1,048 diagnoses, rate 37.6), Broward (588, 29.7), Orange (461, 27.7), Hillsborough (378, 24.3), Duval (273, 28.2), Palm Beach (282, 18.3), and Pinellas (164, 12.2).2

One number deserves to be read as a success. Florida recorded one perinatally acquired HIV diagnosis among babies born in the state in 2023, down from eight in 2022 — an 88% decrease — among 409 infants with perinatal HIV exposure.2 That is what prenatal screening plus prompt antiretroviral therapy plus follow-through produces.

Advocacy — the women who built this field

Almost every improvement described here — the cohort that produced the data, the guidelines that changed on breastfeeding, the trials that enrolled women first — exists because women living with HIV organized to demand it.

SisterLove was founded in 1989 by Dázon Dixon Diallo, MPH, DHL, as the first women's HIV/AIDS and sexual and reproductive justice organization in the southeastern United States, expanding a decade later with SisterLove International South Africa in Johannesburg.21 Its founding insight — that HIV for Black women in the South is a reproductive justice question and not only an infectious disease question — is now conventional wisdom, and was heretical when she said it.

Positive Women's Network–USA was founded in 2008 by 28 women leaders living with HIV, to prepare and involve women, trans, and gender-diverse people living with HIV at every level of policy and decision-making. Its platform runs on six priorities: universal health care; economic justice; sexual and reproductive health, rights and justice; ending HIV criminalization; trans rights, safety and justice; and ending violence against women living with HIV.20

Iris House, founded in 1992 and named for the early HIV activist Iris De La Cruz, was the nation's first HIV/AIDS agency providing family-focused services to women of color affected by HIV, and still offers prevention, education, and support services under executive director Ingrid Floyd.21

In the same interview, Miller names both the harm of criminalization — "HIV criminalization has never improved public health outcomes — it actively undermines them" — and the limit of clinical metrics: "undetectable viral loads, retention in care… those metrics matter, but they only tell us whether someone is surviving. They do not tell us whether someone is living well."22

Community publications including POZ, Positively Aware, and TheBody have carried women's first-person accounts for decades — worth reading alongside the guidelines, for the parts of this experience surveillance data cannot hold.

One boundary this page keeps deliberately: it centers cisgender women, because the epidemiology, trials, and clinical guidance cited here were generated in cisgender women, and flattening trans women into that evidence base serves nobody. Trans women living with HIV face a distinct and severe burden with its own clinical considerations, including hormone therapy interactions and different anal cancer screening thresholds.15 Our page on HIV and trans women takes that up on its own terms.

Next steps — concrete, in order

Everything above condenses into a short list of things to ask for.

1. If you were diagnosed in the last month: start treatment now rather than after the next round of labs, and read our newly diagnosed page for the ninety-day map. Rapid start is the standard, including in pregnancy.8
2. Confirm your cervical screening interval in writing. Cervical cancer rates run three to four times higher by U.S. federal estimates and six-fold by WHO's; your schedule is more frequent than the general-population one.1213
3. If you are 27–45 and never vaccinated against HPV, ask about it under shared clinical decision-making, and about the three-dose schedule.14
4. If you are 45 or older, ask about anal cancer screening — annual symptom assessment for everyone with HIV, and screening from 45 for women where high-resolution anoscopy exists.15
5. Get your weight, blood pressure, lipids, and A1c tracked as a set, especially on an integrase-inhibitor regimen with tenofovir alafenamide.618
6. If you are perimenopausal or postmenopausal, ask directly about hormone therapy and ask which specific contraindication applies to you if the answer is no. The prescribing gap in this population is documented and large.16
7. Bring your contraception question with your regimen name attached. Integrase inhibitors are the reassuring row; efavirenz and implants are the interaction that matters; the levonorgestrel IUD and DMPA are Category 1/2 with antiretroviral therapy.11
8. If children are a possibility — now or in ten years — say so at your next visit. Preconception planning, regimen suitability, and fertility timing are easier addressed early.8
9. If pregnancy is current: ask about infant feeding explicitly. With consistent treatment and viral load under 50 copies/mL for at least three months before delivery, formula, banked donor milk, and breastfeeding are all options to be counseled on — and Child Protective Services has no place in that decision.89
10. If you are not safe, tell someone at the clinic and ask for a plan — 90-day supplies, unlabeled bottles, alternate mailing address, chart flags. The National Domestic Violence Hotline is 1-800-799-7233.17
11. Ask what Ryan White covers where you live, and specifically about Part D if you have children or are pregnant.19 In Florida, start with the state hotline at 1-800-352-2437.2
12. Find other women living with HIV. SisterLove, Positive Women's Network–USA, and Iris House exist for exactly this, and peer connection changes outcomes no prescription touches.2021

None of this is a promise it will be easy to get. It is a list of what is, in 2026, the actual standard of care for women living with HIV — so when a system does not provide it, the system is behind, and you are not asking for too much.